DAXIO sets 2027-2029 growth plan for 12-event U.S. portfolio
DAXIO unveiled a three-year operating plan for its 12 U.S. trade shows, projecting revenue growth from about $12.5 million in 2027 to $30.4 million in 2029. The Florida-based, founder-owned company is leaning on its DealConnect technology, hosted-buyer programs and AI-supported operations as it targets a planned 2030 exit.
Why it matters: - DAXIO is trying to prove that a multi-event trade show portfolio can scale with a lighter cost base than a traditional exhibition organizer. - The company is pairing live events with proprietary technology, which could increase commercial conversion and recurring revenue if the model works as planned. - DAXIO has set a path toward a planned 2030 exit and a $1 billion valuation goal.
What happened: - DAXIO announced a three-year growth plan covering 2027 through 2029 for its 12-event U.S. portfolio. - The company said portfolio sales began in August 2026. - DAXIO is headquartered in Florida and remains founder-owned and independent of private-equity ownership, institutional exhibition groups and external corporate control. - Founder and CEO Dawn Barclay-Ross has about 25 years of international trade show and business-development experience.
The details: - The portfolio includes InfraBuild, PowerXpo, EnerWasteXpo, AgriTechXpo, BioGenomic Health Expo, Advanced Medical Device Show, NextGen MedTech Xpo, InsureCap, SmartMfg, AerospaceXpo, DefenseXpo and TalentTech. - The 12 events span infrastructure, energy, environmental technology, agriculture, healthcare, medical technology, insurance, advanced manufacturing, aerospace, defense and talent technology. - The portfolio provides up to 5,856 stand-equivalent positions. - Current pricing implies about $35.7 million in annual commercial inventory capacity. - That total includes about $32.2 million in exhibition stand inventory plus sponsorship, advertising and Thought Leadership opportunities. - DAXIO projects revenue of about $12.5 million in 2027, $21.4 million in 2028 and $30.4 million in 2029. - The company projects contribution of about $11.2 million in 2027, $20.1 million in 2028 and $29.0 million in 2029. - Contribution margins are expected to rise from about 89.6% to 95.5% over the period. - DAXIO said the model is built around a centralized technology and commercial infrastructure serving multiple independent event inventories. - The company said that structure is designed to expand commercial activity without replicating a traditional large-scale event-company cost base for each exhibition. - DealConnect is DAXIO’s proprietary technology for business qualification and commercial matching. - DealConnect evaluates businesses across more than 500 data points, including capability, compliance and financial criteria. - DAXIO also runs Hosted Buyer programs for qualified buyers with purchasing responsibility and confirmed budgets. - The operating infrastructure includes AI-supported prospect research, data acquisition, outbound communications, response management, lead classification, campaign management and commercial routing. - Human involvement remains in commercial decision-making, closing and physical event operations.
Between the lines: - DAXIO is signaling that the value of its portfolio lies less in individual shows and more in shared infrastructure that can be reused across events. - The company is also framing DealConnect as a differentiator, not just a back-office tool. - The revenue and margin projections are aggressive, so execution across all 12 events will be the key test. - The planned exit and valuation target suggest DAXIO is building toward a sale or other liquidity event rather than a long-term hold.
What's next: - DAXIO said the 2027-2029 plan is the first three full operating years in its broader path to a 2030 exit. - The company plans continued portfolio replication, increased commercial realization and recurring DealConnect revenues. - DAXIO also says it will keep building governance, reporting and controls as the business scales. - Barclay-Ross said the next three years are about demonstrating the model at scale.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
US Healthcare Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.